A small say at most, IMO—I doubt that many MS patients will even know about the new Copaxone option unless they are made aware of it by their neuro.
Moreover, I question whether a 3x per week dosing schedule for a subcutaneous drug is significantly more convenient than a daily one. If the new drug were weekly, that would be a pretty big deal, but thrice-weekly doesn’t gain much in convenience, IMO.
What do you think?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.